The purpose of this study is to examine whether pioglitazone versus placebo can reduce the
conversion rate of impaired glucose tolerance (IGT) to type 2 diabetes mellitus
Phase:
Phase 3
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborators:
Takeda Pharmaceuticals North America, Inc. University of Texas